Cancer & Immunotherapy
Partnerships & Access Track
13-16 October 2025
RAI Congress Centre, Amsterdam
Amsterdam, 13 - 16 October 2025
Schedule
Create your personal agenda –check the favourite icon
Oct 1310:00
Conference pass
Platform Technologies Workshop [AM1]
Platform Technologies Workshop
Jeffrey Almond, Former VP Discovery R&D, Sanofi & Visiting Professor, University of Oxford
Robbert Van der Most, CEO, Vaxxcellence
Kayvon Modjarrad, Executive Director, Viral Vaccines, Pfizer
Session led by: 
Session led by: 
Session led by: 
Session led by: Dyadic International Inc
Joanna Rejman, Head of Formulation, Novo Nordisk Foundation Initiative for Vaccines and Immunity
Oct 1310:00
Conference pass
Biothreats & Disease X Workshop [AM2]
Biothreats & Disease X Workshop
Kayvon Modjarrad, Executive Director, Viral Vaccines, Pfizer
Nicola Lewis, Director of Worldwide Influenza Centre, The Francis Crick Institute
Ana Maria Henao-Restrepo, Lead R&D Blueprint for Epidemics, Health Emergencies Programme (WHE),, World health organisation
Oct 1313:00
Conference pass
Workshop Lunch & Networking Break
Exhibition & Networking
Afternoon Workshops Begin at 2pm:
- Vaccine Safety
- Vaccine Delivery
- Special Populations
Oct 1314:00
Conference pass
Vaccine Safety Workshop [PM1]
Vaccine Safety Workshop
Session led by: 
Debabrata Roy, VAC4EU Executive Board Member, Drug Safety Research Unit
Emilie Karafillakis, European Director, Vaccine Confidence Project, London School of Hygiene and tropical Medicine
Maurizio Sessa, Associate Professor, Pharmacovigilance and Pharmacoepidemiology, University of Copenhagen
Andrew Bate, VP & Head, Safety Innovation & Analytics, Global Safety, GSK
Oct 1314:00
Conference pass
Special Populations Workshop [PM2]
Special Populations Workshop
Rosa Gini, Vice President and Head of the Pharmacoepidemiology Unit, VAC4EU
Oct 1314:00
Conference pass
Vaccine Delivery Workshop [PM3]
Vaccine Delivery Workshop
Maria Alriksson, CEO, Abera Bioscience AB
Create your personal agenda –check the favourite icon
Oct 149:00
Conference pass
Oct 149:05
Conference pass
Keynote Panel: Beyond Borders - Europe’s Strategic Role in Powering Vaccine Innovation and Transforming the Global Vaccine Landscape
Keynotes
- How can Europe’s unique ecosystem of innovation hubs, regulatory frameworks, and public-private partnerships accelerate the next generation of breakthrough vaccines?
- What strategies and incentives are needed to transform Europe’s emerging biotechs and SMEs into tomorrow’s vaccine innovation leaders?
- How can regulatory frameworks evolve to support rapid innovation while maintaining the gold standard in vaccine safety and efficacy?
- In an increasingly complex global health landscape, how can Europe balance domestic innovation priorities with its responsibility to ensure equitable worldwide vaccine access?
Wolfgang Philipp, Principal Adviser, Chief Science Officer, European Commission Health Emergency Preparedness & Response (HERA)
Sibilia Quilici, Executive Director, Vaccines Europe
Keynote Stage
Oct 1410:15
Conference pass
Keynote Panel: Rebuilding Public Literacy and Trust in an Era of Polarisation and Political Uncertainty
Keynotes
- The global impact of U.S. vaccine policy shifts: how political narratives in the U.S. are impacting vaccine confidence and policies worldwide
- The role of governments, media, and public health leaders: what tangible steps can be taken to counter vaccine scepticism and rebuild trust in science?
- What evidence-based strategies are actually working to rebuild trust and increase vaccine uptake in highly polarised environments?
- Tailoring communication approaches to address vaccine hesitancy in different cultural, socioeconomic, and political contexts
- In an increasingly fragmented world, how can we build sustainable cross-border collaborations to strengthen vaccine confidence and literacy?
- AI, trust & biosecurity
Rajinder Suri, Chief Executive Officer, Developing Countries Vaccine Manufacturers Network
Moderator: Seth Ginsberg, Co-Founder and President, Global Healthy Living Foundation
Keynote Stage
Oct 1411:00
Conference pass
Exhibition & Networking Break
Exhibition & Networking
Join us in the Exhibition Hall for1-2-1 partnering and refreshments
Exhibition Hall
Oct 1411:30
Conference pass
Working Group 1: Making Vaccines Real: Aligning Science, Capital, and Supply Chains for Global Impact
Working Group
This high-level discussion focuses on how to translate great science into usable vaccines - on time and at scale. With voices across the value chain, the panel will address:
Trends shaping investment and deal flow in vaccines
The role of flexible manufacturing and platform tech in pandemic preparedness
How innovators and CDMOs can co-develop agile, scalable solutions
Avoiding common CMC and process development disconnects
Creating alignment between product vision, patient need, and production capacity
Ideal for:Developers, Innovators, Investors & CDMOs
Track 1
Oct 1411:30
Conference pass
Working Group 2: Adoption and utilization of virus neutralization assays: Challenges and best practices
Working Group
Session led by: 
Track 2
Oct 1411:30
Conference pass
Working group 4: Can we enhance vaccine effectiveness? Mpox as a model.
Working Group
Session led by: 
Martin Friede, Head, Vaccine R&D Unit, World health organisation
Moderator: Zeil Rosenberg, Executive Vice President, Medical, Tonix Pharmaceuticals
Sina Bavari, EVP and Site Head, Tonix Pharmaceuticals
Track 4
Oct 1411:30
Conference pass
Working Group 5: Building the LMIC Clinical Research Ecosystem of the Future
Working Group
Federico Cubas, Customer Success Director, Emmes Group
Session led by: 
Track 5
Oct 1411:30
Conference pass
Working Group 6: Future-Ready Vaccine Trials: Power of Cross-Sector Collaboration
Working Group
Session led by: 
Yvanne Enever, CEO, PHARMExcel
Saul Faust, Prof of Paediatric Immunology and Infectious Diseases, University of Southampton
Angela Parker, Chief Operating Officer, Fylde Coast Clinical Research
Track 6
Oct 1411:30
Conference pass
Working Groups 3: Introduction to the Korean ARPA-H Initiative: STOREx & DeCAFx
Working Group
Jae Myun Lee, Professor, Yonsei University
Sang Hwan Seo, Director, International Vaccine Institute (IVI)
Track 3
Oct 1412:30
Conference pass
Exhibition & Networking Break
Exhibition & Networking
Join us in the Exhibition Hall for1-2-1 partnering and refreshments
Exhibition Hall
Oct 1412:40
Conference pass
Start-Up Pitches
Start-Up Pitches
12:40 - 'Innovative Viral/RNA Platform for Infectious Diseases and Oncology'Dr Benjamin Damien , CEO, Sagitta Biotech
12:45 - 'Comprehensive Immunopeptidomics Platform for Vaccine Development and Construct Validation'Dr Elise Pepermans, CEO, ImmuneSpec
12:50 - 'Resolving challenges in preventive and therapeutic vaccination through reliable skin drug delivery devices'Dr Vanessa Vankerckhoven, CEO, Idevax
12:55 - 'eFIT: A novel electron beam platform for Vaccine Manufacturing'Daniel Becker, Head of Business Development, KyooBe Tech
13:00 - 'SafeR® Syringes — Engineering Safety and Sustainability'Bruno Vandelanotte, Head of EMEA Sales, Roncadelle Operations
13:05 - 'Unlocking Scalable Biomanufacturing for Advanced Therapies'Dirk Hahneiser, General Manager, Cocoon Bioscience
13:10 - Start-Up Pitch Feedback Panel
Olivier Tak, Junior Partner, Curie Capital BV
Expo Stage
Oct 1414:00
Conference pass
Chair’s Opening Remarks:Next Generation Vaccine Technologies
Technology Showcases
Track 1
Oct 1414:00
Conference pass
COVID & Beyond Track Chair
COVID & Beyond
Kayvon Modjarrad, Executive Director, Viral Vaccines, Pfizer
Track 5
Oct 1414:00
Conference pass
COVID & Beyond Track Chair: Dr Kayvon Modjarrad
COVID & Beyond
Kayvon Modjarrad, Executive Director, Viral Vaccines, Pfizer
Track 5
Oct 1414:00
Conference pass
H5N1 Preparedness: A CRO’s Strategic Response to Emerging Threats
COVID & Beyond
Session led by: 
Luc Gagnon, Global Head Vaccine Sciences, IQVIA Laboratories
Track 5
Oct 1414:00
Conference pass
Enhancing efficiency and safety in cell-based vaccine production: the key roles of Recombinant Insulin and TrypsiNNex®
Formulation & Bioprocess
Track 2
Oct 1414:00
Conference pass
Formulation & Bioprocess Track Chair: Rob Dekker
Formulation & Bioprocess
Rob Dekker, CMC Leader, J&J
Track 2
Oct 1414:00
Conference pass
AMR & Bacterial Vaccines Track Chair
AMR & Bacterial Vaccines
Track 6
Oct 1414:00
Conference pass
Chair's opening remarks
AMR & Bacterial Vaccines
Track 6
Oct 1414:00
Conference pass
Pre-Clinical Development Chair: Prof Matthew Higgins
Pre-Clinical Development
Track 3
Oct 1414:00
Conference pass
Pre-Clinical Development Track Chair: Prof Matt Higgins
Pre-Clinical Development
Track 3
Oct 1414:00
Conference pass
Immune Profiling Track Chair
Immune Profiling
Nuria Guimera, Senior Manager Clinical Science, J&J Innovative Medicine
Track 4
Oct 1414:00
Conference pass
Immunofocusing: How to drive focused or broad antibody responses for optimal vaccine protection
Immune Profiling
Track 4
Oct 1414:05
Conference pass
Immunogenicity assays for rapid response to emerging viral pathogens
Pre-Clinical Development
Session led by:
Track 3
Oct 1414:15
Conference pass
No-wash Immunoassay Technologies - Diversity of Applications within Vaccine Research and Development
Technology Showcases
Session led by: 
Track 1
Oct 1414:15
Conference pass
Advancing Vaccines and Antibodies for Drug-Resistant Infections
AMR & Bacterial Vaccines
- How can vaccines and monoclonal antibodies reduce reliance on antibiotics?
- What’s currently in development - and which high-risk pathogens are still being overlooked?
- Where do vaccines and mAbs facehurdles: trials, endpoints, manufacturing?
- What’s holding R&D back - and what might finally push it forward?
Pete Gardner, Scientific Director, LifeArc
Track 6
Oct 1414:15
Conference pass
Biomarkers Without Borders: Strategic Perspectives from Australian Clinical Sites and Labs for Faster Vaccine Innovation
Immune Profiling
Session led by: 
Track 4
Oct 1414:30
Conference pass
QC Testing with GMP Next Generation Sequencing (NGS) for Vaccine Release
Technology Showcases
Session led by: 
Track 1
Oct 1414:30
Conference pass
Scaling new heights: ionizable lipids for vaccine development, GMP manufacturing, and clinical success
COVID & Beyond
Session led by: 
Track 5
Oct 1414:30
Conference pass
Architects of immunity: Future vaccines using state-of-the-art adjuvants
Formulation & Bioprocess
Session led by: 
Track 2
Oct 1414:30
Conference pass
Navigating the Translational Gap: an Interdisciplinary approach towards Vaccine Development
Pre-Clinical Development
Session led by: 
Track 3
Oct 1414:30
Conference pass
Characterizing vaccine-induced immune responses with Mabtech multiplex assays
Immune Profiling
Session led by: 
Track 4
Oct 1414:45
Conference pass
AI- driven design of broadly protective vaccine antigens
Technology Showcases
Session led by: 
Kaidre Bendjama, CSO, NEC Bio
Track 1
Oct 1414:45
Conference pass
Needle-Free, Cold Chain–Independent Vaccines via Electro-hydrodynamic Processing
Formulation & Bioprocess
Session led by: 
Track 2
Oct 1414:45
Conference pass
Electron Microscopy Mapping of Antibodies
Pre-Clinical Development
Track 3
Oct 1414:45
Conference pass
Fast-track vaccine design & development with ImmuneGPT
Immune Profiling
Session led by: 
Christian Brander, Advisor, Omniscope
Track 4
Oct 1415:00
Conference pass
Self-Amplifying mRNA vaccine and Pandemic Readiness in Japan
COVID & Beyond
Session led by: 
Track 5
Oct 1415:00
Conference pass
The Recombinant Advantage: Enhancing Virus Titer and Stability Without the Serum-Derived Risks
Formulation & Bioprocess
Marcus Curl, VP, Product Applications, InVitria
Track 2
Oct 1415:00
Conference pass
New multivalent vaccines for systemic Salmonella diseases
AMR & Bacterial Vaccines
Track 6
Oct 1415:00
Conference pass
First intranasal vaccine against RSV and hMPV: Metavac®-RSV Proof of Concept with two in vivo studies
Pre-Clinical Development
Track 3
Oct 1415:15
Conference pass
Exhibition & Networking Break
Exhibition & Networking
Join us in the Exhibition Hall for1-2-1 partnering and refreshments
Exhibition Hall
Oct 1415:45
Conference pass
Cell-free Reinvented: Expediting Next Generation Vaccine Development via ALiCE
Technology Showcases
Session led by: 
Track 1
Oct 1415:45
Conference pass
Combining Microbial Innovation with Manufacture: The Road to a First-in-Human pan-Sarbecovirus Vaccine
COVID & Beyond
Track 5
Oct 1415:45
Conference pass
Safety and immunogenicity of the GSK novel AS37 Adjuvant System in combination with HBsAg in a Phase 1/2a, randomized controlled study
Formulation & Bioprocess
Marguerite Koutsoukos, Sr Clinical Science Lead, GSK
Track 2
Oct 1415:45
Conference pass
Highlights of CanSino Bio's innovative, clinical-stage vaccine candidates
AMR & Bacterial Vaccines
Session led by: 
Track 6
Oct 1415:45
Conference pass
Pandemic Readiness: Bridging Innovation and Clinical Implementation
Pre-Clinical Development
Session led by: 
Marta Murreddu, Business Development Director, Cerba Research
Track 3
Oct 1415:45
Conference pass
Beyond Binding: Broad Fc Effector Function Profiling to Accelerate Vaccine and Immunotherapy Developmen
Immune Profiling
Session led by: 
Ashley Brate, Associate Director, SeromYx
Track 4
Oct 1416:00
Conference pass
Thermostability: Formulations That Bridge All Modalities
Technology Showcases
Session led by: 
Track 1
Oct 1416:00
Conference pass
The Next Coronaviruses as Possible Pandemic Threats
COVID & Beyond
Kayvon Modjarrad, Executive Director, Viral Vaccines, Pfizer
Track 5
Oct 1416:00
Conference pass
Panel: Adjuvants: Optimizing Strategies for Emerging Pathogens and Equitable Access
Formulation & Bioprocess
Strategies to overcome IP and licensing barriers to increase global availability of key adjuvant systems.
What is the optimal modular approach to selecting the right adjuvant for a target antigen, especially during pandemic speed?
Balancing cost, risk, and benefit to ensure a continuous supply of excipients during outbreaks.
Exploring the regulatory and economic potential of aligning human and minmal vaccine infrastructures to reduce production costs
Shannon Miller, VP Operations, Inimmune Corporation
Track 2
Oct 1416:00
Conference pass
One Health Strategies to Reduce Antibiotic Use in Human and Livestock
AMR & Bacterial Vaccines
- The role of combination vaccines and new vaccine platforms in preventing bacterial infections
- Case studies of successful vaccine interventions that led to measurable reductions in antibiotic use
- Management and biosecurity strategies: recent progress in biosecurity protocols and livestock management practices
- Global standards to harmonise AMR control across regions & sectors
- Species specific approaches: poultry, swine, aquaculture, and beyond
Track 6
Oct 1416:15
Conference pass
A circular RNA vaccine to treat infectious and other diseases
Technology Showcases
Session led by: 
Peter Weinstein, Chief Executive officer, Circurna
Track 1
Oct 1416:15
Conference pass
The Role of Cellular Immunity in COVID-19 Vaccination: New Insights and Applications
COVID & Beyond
Track 5
Oct 1416:15
Conference pass
Computational Approaches to Antigen Design & Immunofocusing
Pre-Clinical Development
Track 3
Oct 1416:15
Conference pass
Immune profiling to establish connections between innate and adaptive immunity
Immune Profiling
Robbert Van der Most, CEO, Vaxxcellence
Track 4
Oct 1416:30
Conference pass
Candidate Vaccines for MERS-CoV and Related Merbecoviruses
COVID & Beyond
Track 5
Oct 1416:30
Conference pass
Enabling science: supporting vaccine development and innovation at CEPI
Pre-Clinical Development
Track 3
Oct 1416:30
Conference pass
Factors Affecting Parallelism and the Linear Range of an Assay: A Practical Case Study
Immune Profiling
Track 4
Oct 1416:45
Conference pass
Exhibition & Networking Break
Exhibition & Networking
Join us in the Exhibition Hall for1-2-1 partnering and refreshments
Exhibition Hall
Oct 1417:00
Conference pass
Keynote Panel: Vaccines & AMR - Turning Commitment into Practical Action
Keynotes
- How do we channel AMR political commitments into tangible support for early vaccine R&D pipelines
- Where is the strongest evidence that vaccines cut antibiotic use, and what data gaps still limit confidence in investment?
- Which pathogens and settings should shape the next wave of AMR vaccine innovation beyond the usual priorities?
- How do we strengthen the early evidence base so it guides funders, regulators, and developers at the right time?
- What collaboration models between funders, small biotechs, and larger pharma can accelerate early-stage research through to viable candidates?
- How do we keep fragile AMR vaccine pipelines alive and resilient amid global crises, funding pressures, and competing health priorities?
Keynote Stage
Oct 1418:00
Conference pass
Off-site Networking Drinks
Exhibition & Networking
Zuidpool: https://maps.app.goo.gl/g68WXKQRuDkTmVzp9
Create your personal agenda –check the favourite icon
Oct 159:00
Conference pass
Keynote Panel: Rethinking Global Health Threats and Responses: H5N1, Mpox, Measles, Marburg, Climate, Zoonoses, and Emerging Risks
Keynotes
- Pandemic vs. endemic priorities: What’s missing from the global agenda? – Are we too fixated on future pandemics while ignoring the growing threats of endemic infectious diseases (e.g., TB, dengue, H5N1)?
- Climate-driven disease risks: Are we accurately predicting which pathogens will surge due to climate change? (e.g., vector-borne diseases like malaria vs. less-discussed threats). How can we better anticipate less obvious threats?
- How should we be investing in surveillance and R&D? – What innovations (AI, genomics, forecasting) actually have the potential to get ahead of the next crisis?
- How do we ensure that disease prioritisation is driven by science, not politics? – What structural and policy shifts are needed to avoid repeating past mistakes?
- Are we adequately investing in diagnostic capabilities for future threats, or are we overly focused on vaccines and treatments? How can improved diagnostic strategies enhance our ability to detect and respond to emerging threats quickly?
- How can we improve international collaboration in disease surveillance, research, and response while addressing geopolitical challenges and ensuring equitable access to resources?
Keynote Stage
Oct 1510:00
Conference pass
Keynote Panel: Valuing Vaccines Beyond Cost-Effectiveness
Keynotes
- How can we evolve beyond traditional metrics to capture the full societal value of vaccines - from pandemic prevention to economic stability?
- What would a new multidimensional framework for measuring vaccine impact look like, and how could it transform funding priorities?
- How do we bridge the gap between theoretical frameworks and real-world policy adoption - what are the barriers and opportunities?
- As the world faces new health challenges, how can expanded valuation metrics help drive better decision-making in vaccine development and implementation?
Shelly Malhotra, Vice President Global Access & External Affairs, IAVI
Keynote Stage
Oct 1511:00
Conference pass
Exhibition & Networking Break
Exhibition & Networking
Join us in the Exhibition Hall for1-2-1 partnering and refreshments
Exhibition Hall
Oct 1511:30
Conference pass
Engineering a Medical Device for Intranasal Immunization: Ensuring Targeted Delivery and Formulation Stability
AMR & Bacterial Vaccines
Track 6
Oct 1511:30
Conference pass
Doing vaccine trials in a world with increasing vaccine & research hesitancy
Clinical Trials
Session led by: 
Track 3
Oct 1511:30
Conference pass
Chair's opening remarks
One Health & Veterinary
Track 4
Oct 1511:30
Conference pass
High infection rates achieved with the worlds’ first RSV B challenge model; a key component of our RSV-hMPV-PIV combination vaccine efficacy testing platform
Respiratory
Session led by: 
Track 5
Oct 1511:30
Conference pass
Uncovering the Hidden Burden: Diagnostic Limitations and Opportunities for Detection of Respiratory Syncytial Virus (RSV) in Adults
Emerging & Infectious Diseases
Track 1
Oct 1511:30
Conference pass
How can a microneedle manufacturer contribute to the success of cancer vaccine developers?
Biopharma Showcases
Session led by: 
EXPO Stage
Oct 1511:30
Conference pass
Translating Outer Membrane Vesicles (OMVs) from Research to Clinical Manufacturing: Overcoming Challenges and Unlocking Vaccine Potential
Bioprocess & Manufacturing
Session led by: 
Track 2
Oct 1511:40
Conference pass
Self-amplifying mRNA vaccination elicits protection in the upper and lower respiratory tract of naïve non-human primates 6 months after first immunization
Biopharma Showcases
Session led by: 
EXPO
Oct 1511:45
Conference pass
The Microbiome's Role in Infection Prevention: A New Frontier in CHIM Trials
Clinical Trials
Session led by: 
Track 3
Oct 1511:45
Conference pass
Achieving Broad immunological Coverage Through High-Quality, High-Potency vaccines: Solid Technological Foundations in FMD Vaccines
One Health & Veterinary
Session led by: 
Track 4
Oct 1511:45
Conference pass
Oral bivalent vaccine for norovirus protection. Recent improvements to improve immunogenicity and potentially efficacy
Emerging & Infectious Diseases
Session led by: 
Track 1
Oct 1511:45
Conference pass
Innovative Adjuvants for Accessible Global Health
Bioprocess & Manufacturing
Session led by: 
Peter Tygesen, Business Development Director, SPI Pharma
Track 2
Oct 1511:50
Conference pass
mRNAfacturing, a Continuous Manufacturing Solution for All-Scale mRNA-LNP Production
Biopharma Showcases
Session led by: 
EXPO Stage
Oct 1512:00
Conference pass
Raising effective immunity against bacterial Outer-Membrane Proteins with a whole-cell platform: universal and multi-pathogen vaccines
AMR & Bacterial Vaccines
Track 6
Oct 1512:00
Conference pass
Clinical Supplies Logistics for Global Mega Vaccine Trials
Clinical Trials
Session led by: 
Track 3
Oct 1512:00
Conference pass
Between ethics and urgency; the role of non-humane primates in vaccine research
One Health & Veterinary
Session led by: 
Track 4
Oct 1512:00
Conference pass
C1 Technology: Transforming Respiratory Disease Prevention and Treatment with Scalable, Affordable Biomanufacturing
Respiratory
Session led by: 
Track 5
Oct 1512:00
Conference pass
Overview of Historical Safety Data: ACAM2000® [Smallpox and Mpox (Vaccinia) Vaccine, Live]
Emerging & Infectious Diseases
Session led by: 
Track 1
Oct 1512:00
Conference pass
Towards single-administration vaccines: Preclinical studies on HIV and H5N1
Biopharma Showcases
Session led by: 
EXPO Stage
Oct 1512:00
Conference pass
From Lab to Clinic: QC Analytical Methods as a Key Tool for Success Across the New Drug Development Lifecycle
Bioprocess & Manufacturing
Track 2
Oct 1512:10
Conference pass
The journey of the Gorilla Adenoviral Platform: From COVID to HIV vaccines
Biopharma Showcases
Session led by: 
EXPO Stage
Oct 1512:15
Conference pass
AI-Immunology™-Powered Development of a Staphylococcus aureus Vaccine
AMR & Bacterial Vaccines
Track 6
Oct 1512:15
Conference pass
Technological Advancements in Veterinary Vaccines
One Health & Veterinary
Track 4
Oct 1512:15
Conference pass
Beyond Undefined & Serum-Containing Conditions: Chemically Defined VERO-Based Vaccine Production
Bioprocess & Manufacturing
Session led by: 
Marcus Curl, VP, Product Applications, InVitria
Track 2
Oct 1512:30
Conference pass
Multiparametric high content imaging a powerful method to identify new mechanisms of action in AMR research
AMR & Bacterial Vaccines
Track 6
Oct 1512:30
Conference pass
Driving Vaccine Development in LMICs: Case Studies from Norovirus and Polio Trials
Clinical Trials
Track 3
Oct 1512:30
Conference pass
Advancing Influenza Prevention: Latest Clinical Insights on OVX836, a Broad-spectrum T-Cell Influenza Vaccine
Respiratory
Session led by: 
Track 5
Oct 1512:30
Conference pass
Antigen optimization for infectious disease vaccines using AI-Immunology™
Emerging & Infectious Diseases
Session led by: 
Track 1
Oct 1512:30
Conference pass
The development and manufacturing of Human Viral Challenge Agents (HVCA), a safe GMP solution for accelerating vaccine development
Bioprocess & Manufacturing
Session led by: 
Track 2
Oct 1512:45
Conference pass
Exhibition & Networking Break
Exhibition & Networking
Join us in the Exhibition Hall for1-2-1 partnering and refreshments
Exhibition Hall
Oct 1513:00
Conference pass
Working group 7: Securing fundraising for clinical-stage vaccine companies
Working Group
Mario Barro, Head of Infectious Diseases at RA Capital. CEO/President at GIVAX, RA Capital
Giovanni Mariggi, Partner, Medicxi
Track 3
Oct 1513:00
Conference pass
Working Group 8: Power in Partnership: Cross-Sector Collaboration for Vaccine Resilience
Working Group
The vaccine ecosystem is under pressure—from misinformation to declining trust and funding. Join a dynamic session of lightening talks and roundtable discussion to co-create actionable strategies for resilience, collaboration, and rapid response.
Kayvon Modjarrad, Executive Director, Viral Vaccines, Pfizer
Track 5
Oct 1513:00
Conference pass
Working group 9: Rising Stars: Empowering Mid-Career Women in Global Immunisation Leadership
Working Group
What challenges do mid-career women face when transitioning into leadership roles in immunisation?
How can we support professional growth and visibility for women in vaccine R&D and policy?
Lessons from Women Lift Health & other networks
How do gender representation and equity shape immunisation policy and leadership?
Mentorship and networking strategies for career advancement
Balancing field experience with leadership aspirations
Track 6
Oct 1513:00
Conference pass
Start-Up Pitches
Start-Up Pitches
13:00 - 'Proprietary WISIT Platform Delivers Best-in-class Parkinson Vaccine'Markus Mandler, CEO & Founder, Tridem Bioscience
13:05- 'FINVAC: Developing a Universal Intranasal Vaccine Platform'Jenni Vuola, Buisness Development Advisor, Rokote Laboratories Finland
13:10-'Military-grade AI for Protecting the Vaccine Industry from Disinformation Campaigns'Tom Garnett, CEO & Co-Founder, Refute
13:15 - 'A Modular Versatile Platform for Next-generation Immunoengineering'Damian Alvarez-Paggi, CEO,Eureka Nanobioengineering
13:20 - 'Beyond the Needle: A Microneedle Platform Delivering Unprecedented Dose Consistency to Accelerate Vaccine Access'Dr. Fazlul-Hoque Chowdhury, Director, C-Mark Bio
13:25 - 'Monitoring the Antigen-Specific T-cell Response with TCR Sequencing'Dr. Sander Wuyts, CEO & Co-Founder, ImmuneWatch
13:30 - 'AI-disease Simulations: Accelerating Therapeutic Development with Multi-omics Models'Lee Sherlock, CEO & Co-Founder, Meta-Flux
Sander Wuyts, CEO, ImmuneWatch
Expo Stage
Oct 1514:15
Conference pass
Preclinical development of mRNA-based tuberculosis vaccines BNT164a1 and BNT164b1
AMR & Bacterial Vaccines
Track 6
Oct 1514:15
Conference pass
Blueprint to Breakthrough: Standardising Vaccine Trials with AI
Clinical Trials
Track 3
Oct 1514:15
Conference pass
Veterinary regulatory developments and innovations: experiences with implementation
One Health & Veterinary
Track 4
Oct 1514:15
Conference pass
Panel: Why has flu vaccine efficacy stalled and how do we fix it?
Respiratory
- What is holding back flu vaccine efficacy when we are achieving >90% for other vaccines? What strategies can we use to address this?
- Is there a viable business case for high-efficacy flu vaccines? Overcoming low pricing and high cost of superiority trials deterring investment
- What would be needed to justify large-scale investments?
- Balancing seasonal improvements with universal approaches
- Comparing approaches: seasonal improvements, universal approaches, pandemic preparedness, multi-year protection, live attenuated vaccines, rapid synthesis methods
Jeffrey Almond, Former VP Discovery R&D, Sanofi & Visiting Professor, University of Oxford
Roland Zahn, Senior Scientific Director, Head Nonclinical and Translational Immunology & Biomarkers, CDTL Universal Influenza Vaccine & CDTL, Johnson & Johnson
Track 5
Oct 1514:15
Conference pass
Safety, durability and protection of a single-dose TNX-801 mpox vaccine
Emerging & Infectious Diseases
Session led by:
Sina Bavari, EVP and Site Head, Tonix Pharmaceuticals
Track 1
Oct 1514:15
Conference pass
Enabling Intradermal Administration of Vaccines Via Scalable Microneedle Array Patches (MAPs)
Bioprocess & Manufacturing
Track 2
Oct 1514:30
Conference pass
Updates on Vaccine Development for E.Coli: ETEC Phase IIb data in travellers and endemic populations
AMR & Bacterial Vaccines
Track 6
Oct 1514:30
Conference pass
Eliminating the Cold Chain: A Fridge-Free Td Vaccine From Concept to Clinical Trials
Clinical Trials
Track 3
Oct 1514:35
Conference pass
Collaborations and vaccine capabilities in the Global South
International BioClusters
EXPO Stage
Oct 1514:35
Conference pass
Collaborations and vaccine capabilities in the Global South
International BioClusters
EXPO Stage
Oct 1514:45
Conference pass
UK vaccine initiatives
International BioClusters
EXPO Stage
Oct 1514:45
Conference pass
Development of the first recombinant dual-hit glycoconjugate vaccines for Group A Streptococcus
AMR & Bacterial Vaccines
Track 6
Oct 1514:45
Conference pass
Gamma PN a serotype -independent pneumococcal vaccine – early clinical and immunogenicity data
Clinical Trials
Session led by: 
Track 3
Oct 1514:45
Conference pass
Field Implementation Strategies in Wildlife and Livestock
One Health & Veterinary
- Practical aspects of wildlife vaccination programmes: oral bait for ASF in wild boar/feral pigs, lessons from classical swine fever control
- Surveillance strategies and challenges; overcoming practical and ethical challenges in wildlife sampling, balancing active vs. passive surveillance, UK bat surveillance for rabies (APHA Weybridge)
- Evolution of vaccine profiles from containment to eradication stages
- Role of DIVA strategies in eradication programs
- Case study: PPR vaccine transition from live to killed vaccines
Erwin Blomsma, Chief Executive Officer, ViroVet
Track 4
Oct 1514:45
Conference pass
Regulatory Readiness Dashboard: Use of FRPath to communicate regulatory requirements in future public health emergencies
Emerging & Infectious Diseases
Track 1
Oct 1514:45
Conference pass
From Kit to Custom: Development of an Accurate In-House Host Cell DNA and Sizing Assay
Bioprocess & Manufacturing
Session led by: 
Track 2
Oct 1514:55
Conference pass
The Belgian Academic Vaccine Trial Activities
International BioClusters
EXPO Stage
Oct 1515:00
Conference pass
Update on clinical development on a vaccine against Group A Streptococcus
AMR & Bacterial Vaccines
Track 6
Oct 1515:00
Conference pass
Expanding the Toolkit for HPV Research: A Versatile Platform for HPV Vaccine Immunological Studies
Clinical Trials
Session led by:
Track 3
Oct 1515:00
Conference pass
Self-amplifying mRNA vaccines: pandemic and post-pandemic experience
Emerging & Infectious Diseases
Session led by: 
Track 1
Oct 1515:05
Conference pass
China: How are Regulatory Reforms in China Creating Opportunities for Vaccine Development?
International BioClusters
EXPO Stage
Oct 1515:15
Conference pass
The Dutch Vaccine Landscape - Uniting Science, Industry, and Policy through InFECT-NL to Strengthen the Fight Against Infectious Diseases
International BioClusters
Sophie Watertor, pandemic preparedness strategy specialist, INFECTA
EXPO Stage
Oct 1515:15
Conference pass
Next-generation vaccine development and therapeutic antibodies for bacterial pathogens
AMR & Bacterial Vaccines
Track 6
Oct 1515:15
Conference pass
Recent Advances in Universal Flu Vaccines
Respiratory
Track 5
Oct 1515:15
Conference pass
Recent Advances in Universal Flu Vaccines
Respiratory
Track 5
Oct 1515:15
Conference pass
Pandemic Preparedness Efforts in Global Health Security
Emerging & Infectious Diseases
Track 1
Oct 1515:15
Conference pass
Next-Generation Vaccines: Integrating VLP and VLP-cRNA Platforms for Broad-Spectrum, Durable Protection
Bioprocess & Manufacturing
Session led by: 
Track 2
Oct 1515:25
Conference pass
Canada’s Pandemic Capabilities: 5 Regional Vaccine and Pandemic Preparedness Hubs
International BioClusters
EXPO Stage
Oct 1515:30
Conference pass
LTB-SA7, a multicomponent toxoids vaccine against S. aureus in phase I
AMR & Bacterial Vaccines
Track 6
Oct 1515:30
Conference pass
Controlled Human Infection Models in Drug Development
Clinical Trials
Session led by: 
Track 3
Oct 1515:30
Conference pass
Preclinical & Clinical Progress on Clover's RSV+hMPV±PIV3 Combination Vaccines
Respiratory
Session led by: 
Track 5
Oct 1515:30
Conference pass
Assay Standardization for Rare Pathogens within CEPI’s Centralized Laboratory Network
Emerging & Infectious Diseases
Track 1
Oct 1515:30
Conference pass
Optimizing Downstream Processing for Next-Generation Vaccine Development
Bioprocess & Manufacturing
Session led by: 
Track 2
Oct 1515:45
Conference pass
Beyond the bladder: vaccine development for Enterobacteriaceae associated with UTI
AMR & Bacterial Vaccines
Track 6
Oct 1515:45
Conference pass
Immunogenicity of a single-dose adenovirus-vectored rabies vaccine in a Phase Ib/II clinical trial
One Health & Veterinary
Track 4
Oct 1515:45
Conference pass
Oral Covid Vaccine - Clinical Update from phase 1 to phase 2B
Respiratory
Session led by:
Track 5
Oct 1515:45
Conference pass
Comparative analysis of evidence generation approaches for vaccines in outbreak settings
Emerging & Infectious Diseases
- Significant progress in research on arboviruses and flaviviruses; dengue, tick-borne encephalitis, yellow fever
- Evolving regulatory approaches for trials, adapting to new technologies and global health challenges
- Chikungunya case study; navigating multi-country licensure challenges and innovative regulatory approaches
- Evidence generation under pressure; balancing urgent public health needs with trial rigour
- Post-licensure trials in non-licensed markets; regulatory, ethical and operational complexities
- How global regulators are evolving approaches to support both emergency responses and robust scientific evaluation during outbreaks
Manuela Mura, scientific officer, European Medicines Agency
Track 1
Oct 1516:00
Conference pass
Conjugate Vaccines for AMR: Advancing Chemistry and Expanding Pathogen Coverage
AMR & Bacterial Vaccines
- Explore new developments in conjugate vaccine chemistry, including click chemistry and novel formulations.
- Highlight the clinical success and market impact of high-valent conjugate vaccines targeting bacterial pathogens such as pneumococcal formulations.
- The role of conjugate vaccines in reducing bacterial infections and antibiotic use, contributing to AMR mitigation.
- Discuss future directions and opportunities for high-valency conjugate vaccine development in addressing diverse pathogens of AMR-priority status
Track 6
Oct 1516:00
Conference pass
Leveraging Multi-Site Research Companies for Successful Clinical Trial Execution
Clinical Trials
Session led by: 
Track 3
Oct 1516:00
Conference pass
Panel: Non-Technical Barriers to Vaccine Adoption in Livestock and Companion Animals
One Health & Veterinary
Track 4
Oct 1516:00
Conference pass
New Tuberculosis Vaccines
Respiratory
Track 5
Oct 1516:00
Conference pass
Accelerating Vaccine Development: End to End Manufacturing and Innovation Platform
Bioprocess & Manufacturing
Session led by: 
Track 2
Oct 1516:15
Conference pass
Serological assays: a tool for vaccine evaluationa and pandemic preparedness
Clinical Trials
Session led by: 
Track 3
Oct 1516:15
Conference pass
Beyond Bird Flu: Seqirus’ Blueprint for Future Outbreaks
Respiratory
Track 5
Oct 1516:30
Conference pass
V212: A serotype-independent, peptide antigen, pneumococcal vaccine based on a fully synthetic, self-adjuvanting virus-like particle
Clinical Trials
Session led by: 
Track 3
Oct 1516:30
Conference pass
From Underestimation to Insight: Advances in Disease Burden Estimations for Respiratory Syncytial Virus (RSV) in Adults
Respiratory
Track 5
Oct 1516:30
Conference pass
Digital Strategies to Accelerate End-to-end Process Characterization
Bioprocess & Manufacturing
Session led by: 
Track 2
Oct 1516:45
Conference pass
Exhibition & Networking Break
Exhibition & Networking
Join us in the Exhibition Hall for1-2-1 partnering and refreshments
Exhibition Hall
Oct 1517:00
Conference pass
Keynote Panel: Frontier Technologies in Vaccine Innovation: What are the market trends and how is innovation addressing evolving health threats
Keynotes
- How does the current pipeline look and what types of vaccines can we anticipate?
- The importance of diversity in technologies
- How is AI-driven vaccine design, ML, Synthetic biology, engineering antigens, and novel delivery systems changing the way develop vaccines?
- Personalised vaccinology; examining the future of individualised vaccines
- Dual Markets & Sustainability: Managing the LMIC-HIC divide while pushing for eco-friendly design and novel vaccines
Jerome Kim, Director General, ivi
Keynote Stage
Create your personal agenda –check the favourite icon
Oct 169:00
Conference pass
Exhibition & Networking Break
Exhibition & Networking
Join us in the Exhibition Hall for1-2-1 partnering and refreshments
Exhibition Hall
Oct 169:30
Conference pass
Clinical Trials Chair : Michael Caldwell
Clinical Trials
Track 3
Oct 169:30
Conference pass
The Vaccine Innovation Pathway: The UK’s First Clinical Trial Delivery Accelerator
Clinical Trials
Angela Parker, Chief Operating Officer, Fylde Coast Clinical Research
Track 3
Oct 169:30
Conference pass
Manufacturing Technologies Chair
Manufacturing Technologies
Track 2
Oct 169:30
Conference pass
Valuation for Fundraising and Licensing
Partnerships & Access
Track 5
Oct 169:30
Conference pass
Bridging Access and Equity through Digital Networks
Supply & Logistics
Track 4
Oct 169:30
Conference pass
Supply & Logistics Track Chair
Supply & Logistics
Track 4
Oct 169:30
Conference pass
Supply & Logistics Track Chair: Reda Sadki
Supply & Logistics
Track 4
Oct 169:30
Conference pass
Panel: Unlocking the Potential of Real-World Evidence for Vaccines in LMICs: Opportunities, Challenges, and Collaborations
Neglected Diseases & Global Health
Eric Remera, Division Manager, Research Innovation and Data Science, Rwanda Biomedical Centre
Pesh Doubleday, Real World Evidence Lead, Global Health, IQVIA
Dominique Milea, RWE head Global Health, GSK
Track 1
Oct 169:45
Conference pass
Korea's Health Initiative to address unmet medical needs: Investing in a platform for Personalized Cancer Vaccine development
Manufacturing Technologies
Advancing Vaccine Innovation and Preparedness through the Korean ARPA-H Initiative
Track 2
Oct 1610:00
Conference pass
Taking a multi-antigen vaccine into clinical trials
Clinical Trials
Track 3
Oct 1610:00
Conference pass
Irradiation technologies for vaccine manufacturing
Manufacturing Technologies
Track 2
Oct 1610:00
Conference pass
The Role of Incubators & Funding Models in Advancing Vaccine Development
Partnerships & Access
Track 5
Oct 1610:00
Conference pass
The Gold Standard QS-21 for Vaccine Adjuvants - Delivered by Desert King
Supply & Logistics
Session led by: 
Track 4
Oct 1610:00
Conference pass
Introduction to a Therapeutic DNA-Launched mRNA Vaccine for the Treatment of Tuberculosis
Cancer & Therapeutic Vaccines
Track 6
Oct 1610:15
Conference pass
From API to Patient: Building an End-to-End Vaccine Supply Chain for Global Impact
Supply & Logistics
Track 4
Oct 1610:30
Conference pass
One Concept, Many Realities: Dimensions of Real-World Evidence in Practice
Clinical Trials
Session led by: 
Duco Veen, Manager, Julius Clinical
Track 3
Oct 1610:30
Conference pass
Innovative approaches to stabilize RSV preF protein & Ad26 vector vaccine
Manufacturing Technologies
Track 2
Oct 1610:30
Conference pass
Systemic and Shifting Global Market Stressors: Navigating Funding, Partnerships and Innovation in a Volatile Era
Partnerships & Access
- Barriers to vaccine investment: high R&D costs, uncertain returns, market distortions, and demand uncertainty
- Fiscal austerity, transactional aid, and shifting priorities affecting funding, partnerships, and access
- Integrating vaccines into AMR strategies in LMICs to strengthen systems and attract cross-sector investment
- Incentives to sustain R&D and manufacturing
- Scalable solutions: blended finance, pooled procurement, value-based pricing
- Case studies: GAVI AMC, CEPI equity clauses, pharma–NGO coalitions
Track 5
Oct 1610:30
Conference pass
Expanding the Toolbox: VFI's Open-Access Portfolio of Vaccine Adjuvants
Supply & Logistics
Track 4
Oct 1610:30
Conference pass
BioNTech’s Oncology Pipeline: Combining mRNA Cancer Immunotherapies with Next-Gen Immunomodulators and Targeted Therapies
Cancer & Therapeutic Vaccines
Track 6
Oct 1610:30
Conference pass
HIV-1 Vaccines and bnAbs: where do we go from here?
Neglected Diseases & Global Health
Track 1
Oct 1610:45
Conference pass
Pragmatic trials, the crown jewel of real-world evidence
Clinical Trials
Track 3
Oct 1610:45
Conference pass
Update on clinical development on a bivalent vaccine against S. Typhi and Paratyphi A
Neglected Diseases & Global Health
Track 1
Oct 1611:00
Conference pass
The US Regulatory Environment: Implications for Clinical Development Strategy
Clinical Trials
Track 3
Oct 1611:00
Conference pass
On-Demand Vaccine Distribution using Drones to Remote Communities
Supply & Logistics
Track 4
Oct 1611:00
Conference pass
Targeting Chronic Viral Infections Through Immunotherapeutics: Moving Towards the Golden Age of Better Health
Cancer & Therapeutic Vaccines
Track 6
Oct 1611:00
Conference pass
Panel: Bridging the gaps: Overcoming the remaining challenges in vaccine development for global health
Neglected Diseases & Global Health
- The role of epidemiology and disease prevalence data in setting priorities for vaccine development
- Navigating uncertainty: how to make evidence-based decisions when data is scarce or incomplete
- What we can learn from successful (and stalled) vaccine efforts across other global health diseases
- How innovation in immunogenicity and correlates of protection can accelerate progress in emerging and respiratory disease threats
- Ensuring sustainability: What’s needed to support long-term vaccine manufacturing and R&D infrastructure in LMICs
Simone Blayer, Global Head CMC and Non Clinical Toxicology, PATH
Moderator: Petro Terblanche, Chief Executive Officer, Afrigen Biologics (Pty) Ltd
Track 1
Oct 1611:30
Conference pass
Exhibition & Networking Break
Exhibition & Networking
Join us in the Exhibition Hall for1-2-1 partnering and refreshments
Exhibition Hall
Oct 1612:30
Conference pass
Clinical Trials Track Chair
Clinical Trials
Track 3
Oct 1612:30
Conference pass
Showcasing & Utilising Established Challenge Models: Improving A Malaria Vaccine Candidate Using CHIM
Clinical Trials
Track 3
Oct 1612:30
Conference pass
More than 13-fold increase in viral vaccine titers using novel nanofiber microcarriers in Vero cell cultures
Manufacturing Technologies
Session led by: 
Christel Fenge, CTO, Cellevate AB
Track 2
Oct 1612:30
Conference pass
Strategic Partnerships in Vaccine Development: Platforms vs. Products
Partnerships & Access
- How are biopharma partnerships evolving?
- Evaluating technology-led vs. product-led partnership models
- Bridging academic immunology discoveries to biotech commercialisation
- Balancing partner interests in multi-stakeholder vaccine projects
- Structuring deals and best practices in securing platform technology partnerships
Moderator: Jeffrey Almond, Former VP Discovery R&D, Sanofi & Visiting Professor, University of Oxford
Petro Terblanche, Chief Executive Officer, Afrigen Biologics (Pty) Ltd
Track 5
Oct 1612:30
Conference pass
Panel: End-to-End Vaccine Supply Chains - From Local Manufacturing to Last-Mile Delivery
Supply & Logistics
- How regional manufacturing, pooled procurement, and demand aggregation are reshaping vaccine supply ecosystems
-
Using AI & real-time data to forecast needs, and manage inventory across fragmented systems
-
Lessons learned in reaching remote populations
-
Rethinking global and local sourcing: how to build adaptable, resilient supply chains in the face of future outbreaks
Maria Stavridou, Head of Vaccine & Immunisation Programmes, UKHSA
Track 4
Oct 1612:30
Conference pass
AI-Driven Neoantigen Selection: Technology Advancements and Clinical Applications
Cancer & Therapeutic Vaccines
Track 6
Oct 1612:30
Conference pass
Developing a sustainable concept for rapid evidence generation in future emergencies
Neglected Diseases & Global Health
Track 1
Oct 1612:45
Conference pass
Predicting Protection: The Role of CoPs and Immune Markers in Next-Gen Clinical Trials
Clinical Trials
Christine Dahlke, Translational Immunology Lead, CEPI
Track 3
Oct 1612:45
Conference pass
From DNA to Dose: Automated Cell-Free Systems for Decentralised Vaccine Production
Manufacturing Technologies
Track 2
Oct 1612:45
Conference pass
Combination Vaccines as Equity Accelerators: Can Co-Administration Ease the Burden on Health Systems?
Neglected Diseases & Global Health
- Exploring the scientific, clinical, and operational benefits of vaccine co-formulation for equity, efficacy, and broader protection – what diseases cluster geographically (e.g., schiso & dengue?)
- Challenges in developing compatible combination vaccines; ensuring immunogenic compatibility
- Health system resilience, reducing immunisation burdens to enhance vaccine access in resource-limited settings
- Economic insights and equity considerations from LMIC perspective – how can combination vaccines cut delivery costs by 30-40%?
Kutub Mahmood, Scientific Director, PATH
Track 1
Oct 1613:00
Conference pass
Immunogenicity of the J&J Ebola Vaccine: Closing the Pregnancy Data Gap
Clinical Trials
- Immunogenicity of the J&J vaccine regimen in pregnant women
- Implications for maternal and fetal protection during Ebola outbreaks
Track 3
Oct 1613:00
Conference pass
RNAbox: A continuous RNA production platform process-in-a-box for rapid disease-agnostic RNA vaccine & therapeutic development and mass-manufacturing at high-quality and low-cost
Manufacturing Technologies
Track 2
Oct 1613:00
Conference pass
Leveraging the Potential of DNA Immunotherapy: Long-Term Efficacy in HPV-6 & 11 Recurrent Respiratory Papillomatosis (RRP)
Cancer & Therapeutic Vaccines
Track 6
Oct 1613:30
Conference pass
Product and trial design considerations on the path towards a vaccine to combat opioid overdose
Clinical Trials
Track 3
Oct 1613:30
Conference pass
The Role of NGOs in Stakeholder Engagement
Partnerships & Access
Track 5
Oct 1613:30
Conference pass
Digital twins for vaccine manufacturing: a modelling pathway towards preparedness and fast response.
Supply & Logistics
- What is a digital twin, and how can it improve decision-making across vaccine manufacturing?
- Real-world example: key components of a digital twin model and the types of decisions it can support
- Scenario planning for outbreak preparedness and agile response: how digital twins enable forward-looking strategies both for manufacturers as well as prepardness agencies
- Industry and government perspectives: where digital twins deliver value across stakeholders, and what challenges remain
Gemma Lahuerta Buira, Parenteral Development Director, LABORATORIO REIG JOFRE, S.A.
Track 4
Oct 1613:30
Conference pass
Regulating Personalised mRNA Cancer Immunotherapies: AI Innovation vs Regulation, Global Impact and Industry Readiness
Cancer & Therapeutic Vaccines
- How will MHRA’s classification of these therapies as ATMPs impact global regulatory alignment?
- What are the key risks of AI performance drift and bias in personalised therapy development?
- How will classifying algorithms as SaMDs shifting AI-driven selection to an IVD regulatory framework disrupt existing trial, manufacturing and quality control models? Should AI-driven neoantigen selection be classified under IVD regulations, or should it remain part of GMP-regulated manufacturing?
- What industry best practices exist for balancing regulatory compliance with the rapid release of individualised therapies?
Track 6
Oct 1613:45
Conference pass
Local and global networks for strengthening the TB vaccine development chain
Partnerships & Access
Track 5
Oct 1613:45
Conference pass
Vaccine Policy in Polycrisis: Sustaining Immunisation Access Under Pressure
Neglected Diseases & Global Health
- Translating WHO guidelines into rapid, flexible decision-making
- Effective health system triage during chronic collapse
- Maintaining vaccine funding amid geopolitical disruptions: insights from EU budget cuts, US-Gulf state bridging finance, and UAE crisis funding mechanisms.
- Practical innovations in crisis vaccine delivery
- Accelerating R&D and policy adaptations under crisis conditions
Track 1
Oct 1614:00
Conference pass
Panel: Challenge Models in Vaccine Development — From Established Tools to Emerging Frontiers
Clinical Trials
- Leveraging proven challenge models: what are we learning and how are they being applied in modern trials?
- Exploring new and proposed challenge models: assessing scientific value, safety, and ethical boundaries
Track 3
Oct 1614:00
Conference pass
Strengthening Partnerships and Local Networks for Infectious Disease Trials
Partnerships & Access
- Identifying and leveraging local partnerships for clinical trials in endemic regions
- Local vs. Global Execution: Can we effectively run endemic country clinical trials, or do we need new frameworks?
- How do geopolitical factors impact trial execution and long-term sustainability?
- Evaluating the effectiveness of existing networks for global health collaborations; Are current partnerships enough, or do we need new collaborative models?
- How can industry and academia ensure equitable, lasting infrastructure for future trials? Strategies for building sustainable partnerships in resource limited settings
Dakshina Reddy, Head of Global Regulatory Strategy and Operations, Bill & Melinda Gates Medical Research Institute
Track 5
Oct 1614:45
Conference pass
Exhibition & Networking Break
Exhibition & Networking
Join us in the Exhibition Hall for1-2-1 partnering and refreshments
Exhibition Hall
Oct 1615:00
Conference pass
Keynote Panel: Life-Course Immunisation: Are Combination Vaccines the Only Viable Path Forward for Adults?
Keynotes
- Evaluating the economic and societal case for routine adult and life-course immunisation,
- What next-generation combination vaccines are approaching approval, and when will health systems realistically adopt them?
- Will standalone new vaccines remain viable, or is the future exclusively in combination vaccines?
- Strategies for integrating novel antigens into existing vaccine presentations and delivery systems
- Policy, procurement, and health system strategies to sustainably deliver true life-course immunisation.
Jerome Kim, Director General, ivi
Jennifer Moisi, VP, Global Medical Franchise Lead, Bacterial and Vector Borne Vaccines, Pfizer
Keynote Stage
last published: 15/Oct/25 11:35 GMT
Created by
Terrapinn is proud to be a member of isla.
Working together to build sustainable events